Market news

Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. The confirmation of TRUTAKNA's Phase III success sits against a wider backdrop of...

Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex.

Vera Therapeutics, Inc. gets FDA accelerated approval for Trutakna in IgA nephropathy, but competition and pricing risk remain. Click for this VERA update.

Vera Therapeutics (NASDAQ:VERA) shares rose 13% on Tuesday after the company reported that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of its ORIGIN 3 trial in adults with primary IgA nephropathy. The company said the results showed that TRUTAKNA stabilised estimated glomerular filtration rate, or eGFR, and reduced kidney disease progression through two years in patients considered at risk of disease progression.

Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.

Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Cantor Global Healthcare Conference 2026Format: Fireside Chat and 1x1 investor meetings Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=395559

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Vera Therapeutics (VERA) has an average rating of buy and mean price target of $81.86, according to

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026. BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeu

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D., Ph.D., Vera’s new Chief Regulatory Officer, u

Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression. The company said TRUTAKNA is the first and only BAFF and APRIL inhibitor indicated to redu

Vera Therapeutics recently received FDA accelerated approval for TRUTAKNA™ (atacicept-vymj), a first-in-class dual BAFF/APRIL inhibitor to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. This approval, based on interim Phase 3 data showing meaningful proteinuria reductions, marks Vera’s first commercial therapy and introduces a home-use weekly autoinjector option targeting the immunological drivers of IgA nephropathy. We’ll now examine how...

Vera Therapeutics has delivered a strong 184.9% return over the past 5 years, yet its valuation checks and current market multiples point to a stock that may now be leaning expensive rather than clearly cheap. With accelerated FDA approval for Trutakna helping to reshape expectations, the question is how much of that optimism is already reflected in the price. The 184.9% 5 year return suggests long term holders have already seen substantial gains, which can limit upside if expectations are...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Vera Therapeutics (VERA) has drawn fresh attention after the US Food and Drug Administration granted accelerated approval for TRUTAKNA to treat adults with IgA nephropathy who are at risk for disease progression. See our latest analysis for Vera Therapeutics. The FDA decision sits against a mixed share price backdrop for Vera Therapeutics, with a 30 day share price return of 33.45% but the year to date share price return still down 12.69%. At the same time, the 1 year total shareholder return...

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief Regulatory Officer of Vera Therapeutics, is planning to retire and transition to the role of Strategic Advisor in the third quarter of this year after a successful tenure at the company, including the recent accelerated approval of Vera Therapeutics’ first

Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins linked to IgA nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.1 Investor webcast is scheduled for July 7 at 4:30 pm EDT. A Media Snippet accompanying this announcement is available by clicking on this link. BRISBANE,